MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

18F-FDG PET brain in Parkinsonism

F. Amod (Durban, South Africa)

Meeting: 2018 International Congress

Abstract Number: 1001

Keywords: Parkinsonism, Positron emission tomography(PET)

Session Information

Date: Sunday, October 7, 2018

Session Title: Parkinsonism, MSA, PSP (Secondary and Parkinsonism-Plus)

Session Time: 1:45pm-3:15pm

Location: Hall 3FG

Objective: To determine if 18F-FDG PET can differentiate Parkinson’s Disease from Parkinson’s-Plus syndromes

Background: Parkinsonism is a clinical syndrome of tremor, rigidity, bradykinesia and postural instability. PD is the commonest cause of parkinsonism. The other neurodegenerative causes are Multiple Systems Atropy (MSA), Progressive Supranuclear Gaze Palsy (PSP), Dementia with Lewy Bodies and Corticobasal Degeneration (CBD). These are known as the Parkinson’s -Plus syndromes (PPS). These forms of parkinsonism do not respond well to therapy and are associated with a poorer prognosis. Differentiating PD from PPS is therefore vital. However, two pathological studies have shown that the diagnostic accuracy of PD is only 76%. Movement disorder services improve the diagnostic accuracy of PD with a positive predictive value of 99%, however these services are not readily available and a marker for differentiating PD from PPS is required. A number of studies have used 18F-FDG PET to differentiate PD from PPS.

Methods: Patients with parkinsonism seen at the Neurology department from 2007-2017 who had an 18F-FDG PET were included in the study. All patients were given an 18F-FDG PET diagnosis by a Nuclear Medicine physician blinded to the clinical diagnosis. The criteria for disease related metabolic patterns was based on Eidelberg et al (1994). [Figure 1]. This was compared to a final clinical diagnosis diagnosis by a Neurologist in the Movement Disorder Service. Sensitivity, specificity, positive and negative predictive values were calculated. Our Neurology services are at a Tertiary Hospital in Durban, South Africa with a population of 11 million persons. Levodopa was withheld for 12 hours prior to 18F-FDG PET.

Results: 80 patients were included in the study, 53 had PD and 27 had PPS (10 PSP, 7 MSA, 8 DLB and 2 CBD). 18F-FDG PET diagnosis of the 53 PD patients: 48 were diagnosed as PD, 1 DLB, 2 MSA, 1 was given the diagnosis Frontotemporal Dementia on PET scan and 1 patient was diagnosed as HIV associated neurocognitive disorder. 18F-FDG PET diagnosis of the 27 PPS: 24 patients were correctly diagnosed and classified by 18F-FDG PET and 3 PPS patients were misdiagnosed as PD. Table 1 shows the characteristics of the 80 patients with parkinsonism. Patients with PPS had a higher UPDRS score with a shorter disease duration and used a lower dose of levodopa compared to PD patients. Table 2 shows the results of the patients.

Conclusions: 18F-FDG PET can differentiate PD from PPS with an accuracy of 90%.

References: 1. Berti, V., L. Mosconi, and A. Pupi, Brain: normal variations and benign findings in fluorodeoxyglucose-PET/computed tomography imaging. PET Clin, 2014. 9(2): p. 129-40. 2. Brown, R.K., et al., Brain PET in suspected dementia: patterns of altered FDG metabolism. Radiographics, 2014. 34(3): p. 684-701. 3. Eckert, T., et al., FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage, 2005. 26(3): p. 912-21. 4. Hughes, A.J., et al., The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain, 2002. 125(Pt 4): p. 861-70. 5. Hughes, A.J., et al., Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry, 1992. 55(3): p. 181-4. 6. Litvan, I., Recent advances in atypical parkinsonian disorders. Curr Opin Neurol, 1999. 12(4): p. 441-6. 7. Meyer, P.T., et al., (18)F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment. J Nucl Med, 2017. 58(12): p. 1888-1898.

To cite this abstract in AMA style:

F. Amod. 18F-FDG PET brain in Parkinsonism [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/18f-fdg-pet-brain-in-parkinsonism/. Accessed May 16, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/18f-fdg-pet-brain-in-parkinsonism/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley